#Czech Republic #Neuromodulation #Ostrava #Stimvia #URIS

Stimvia's Ambitious Expansion Plans

Stimvia, a pioneering medical technology company based in the Czech Republic, has taken a significant step forward in its mission to enhance the treatment landscape for overactive bladder (OAB). The company recently announced a considerable expansion of its scientific advisory board and commercial leadership to boost the global market rollout of its flagship therapy, URIS®.

Strengthening Clinical Leadership

One of the core components of this expansion is the enhancement of Stimvia's scientific advisory board, which now includes top urology experts from the United States, the UK, and across Europe. This strategic move not only aims to amplify the clinical and scientific credibility of Stimvia’s offerings but also positions the company as a leading pioneer in the field.

The newly appointed members bring a wealth of knowledge and experience. Among them is Dr. David R. Staskin, a well-respected urologist from Boston with extensive expertise in lower urinary tract dysfunction and a rich history in medical device development. He is joined by Prof. Alan J. Wein, MD, PhD (Hon), a distinguished figure in OAB research who previously served as the chief of urology at the University of Pennsylvania.

Alongside them are Prof. Christopher R. Chapple, a renowned expert in functional and reconstructive urology from the UK, and Prof. Bertil Blok from the Netherlands, a specialist in neuro-urology. The collective experience of these experts fortifies Stimvia’s capacity to engage with leading clinicians, foster evidence development, and gain trust from healthcare partners and investors.

Building a Commercial Engine

In addition to enriching its advisory board, Stimvia is ramping up its commercial capabilities by bringing in top-tier talent for international market growth. Dr. David da Silva has been appointed as the head of global sales and market development. His more than ten years of leadership experience with notable MedTech companies such as Medtronic and Stryker will be pivotal in forging scalable distribution partnerships and strategies for market entry across Europe, Latin America, and other key regions.

Furthermore, Alim Topdag, MSc, has taken on the role of director for sales and business development for markets outside the United States. He will drive sales and business development in priority areas, leveraging distribution partnerships and direct sales models while also supporting the clinical and technical implementation of URIS®.

A Robust Foundation for URIS®'s Global Launch

These efforts demonstrate Stimvia's commitment to establishing a robust foundation for URIS® as it navigates the international landscape. By combining leading clinical advisory with enhanced commercial leadership, the company is not only preparing for the global market introduction of URIS® but is also setting the stage for the next phase of growth within the global urology markets.

With a focused strategy and a strong team in place, Stimvia is poised to make a meaningful impact in the treatment of OAB, marking a new chapter in patient care capabilities while striving to improve lives worldwide.